Meridian Bioscience, Inc. Signs Agreement With Premier, Inc. To Offer Its Hospitals Molecular Diagnostic Tests And Instruments For C. Difficile, Group B Streptococcus, Group A Streptococcus, Bordetella Pertussis, And Mycoplasma Pneumoniae

CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene® molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene molecular platform without individual negotiations.

Help employers find you! Check out all the jobs and post your resume.